Here, we provide new insight by showing that CD155 but not CD112 is expressed at higher levels in AML than in ALL, and this difference partly accounted for the lower ERK activation and anti-tumor function against AML than against ALL. The gene discussed is NECTIN2; the disease is acute myeloid leukemia.